S Biomedics
에스바이오메딕스 · 304360
Health Care Pharmaceuticals · KOSDAQ
Market cap US$256.7M (₩354.2B)
Overview
S Biomedics develops stem-cell therapies, medicines made from living cells that are grown and processed outside the body, aimed at treating hard-to-cure, rare, and chronic diseases where conventional drugs have limited effect.
Its products and pipeline target patients and healthcare providers across multiple disease areas. Listed on KOSDAQ, Korea's tech and small-cap board, the company's core business is stem-cell therapy research, development, and production, while a subsidiary handles medical devices and anti-ageing cosmetic products.
Summary is AI-generated and may contain errors · figures from DART filings
Financials
Source: DART · FY ending Dec · latest FY2025Revenue
- FY2023US$9.5M
- FY2024US$10M
- FY2025US$12M
Operating profit
- FY2023−US$4.3M
- FY2024−US$3.9M
- FY2025−US$6M
Net income
- FY2023US$770.4K
- FY2024−US$4.2M
- FY2025US$770.2K
Key ratios (FY2025)
Why it matters
Its subsidiary, S-Tepharm, was established as a dedicated sales and manufacturing entity and operates its own production facility for anti-ageing aesthetic products.
Price charts coming soon
Interactive price history isn't here yet. Would you use it?